Skip to main content

CHRS

Stock
Health Care
Biotechnology

Performance overview

CHRS Price
Price Chart

Forward-looking statistics

Beta
2.28
Risk
98.60%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Company info

SectorHealth Care
IndustryBiotechnology
Employees341
Market cap$193.9M

Fundamentals

Enterprise value$301.9M
Revenue$272.3M
Revenue per employee
Profit margin-48.09%
Debt to equity-1.63

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$0.44
Dividend per share
Revenue per share$2.36
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$1M
Put-call ratio

Macro factor sensitivity

Growth+2.5
Credit+7.4
Liquidity-1.3
Inflation-2.6
Commodities-0.0
Interest Rates-2.9

Valuation

Dividend yield0.00%
PEG Ratio-3.00
Price to sales0.34
P/E Ratio-3.00
Enterprise Value to Revenue1.11
Price to book-0.51

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.32 per share a year ago.

Zacks Investment Research (May 12, 2025)
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

On Tuesday, Coherus BioSciences, Inc. CHRS entered into an asset purchase agreement with Intas Pharmaceuticals Ltd for the divestiture of the Udenyca (pegfilgrastim-cbqv) franchise for up to $558.4 million.

Benzinga (December 3, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free